In a report released today, Marc Frahm from Cowen & Co. maintained a Buy rating on Adaptimmune Therapeutics (ADAP). The company’s shares opened today at $6.53, close to its 52-week low of $5.73.
According to TipRanks.com, Frahm is a 1-star analyst with an average return of -8.1% and a 38.9% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Gritstone Oncology Inc, and Blueprint Medicines.
Adaptimmune Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17, a 160.3% upside from current levels. In a report issued on October 22, Raymond James also maintained a Buy rating on the stock with a $16 price target.
.
See today’s analyst top recommended stocks >>
Based on Adaptimmune Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $43.31 million. In comparison, last year the company had a GAAP net loss of $883.3K.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADAP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.
